Roche

Olema Pharmaceuticals (OLMA) Soars Over 200% After Roche Breast Cancer Trial Win — What It Means for Palazestrant and Investors on November 18, 2025

Why OLMA Stock Is Exploding Today Olema Pharmaceuticals didn’t publish a press release or file anything with the SEC this morning. Yet, its stock rocketed nearly threefold in pre‑market trading on Tuesday, November 18, 2025. TipRanks+1 The real catalyst comes from Roche. Roche’s giredestrant delivers a landmark Phase 3 win Roche’s Genentech unit announced that giredestrant, its investigational oral selective estrogen receptor degrader (SERD), hit the primary endpoint in the Phase 3 lidERA trial in early-stage ER+/HER2- breast cancer. RTT News+1 Key points from today’s breast cancer data: For Olema, none of that is its own data — but it’s

18 November 2025

Swiss Stock Market Today, November 18, 2025: SMI Slips as Roche Soars, ABB, Zurich and ams-Osram Drag the Index

The Swiss Market Index (SMI) traded lower on November 18, 2025, as global risk-off sentiment weighed on cyclicals and financials. Roche surged on breakthrough breast cancer data, while ABB, Zurich Insurance and ams-Osram fell after major investor updates and earnings news Market overview: SMI lower despite a powerful Roche rally The Swiss stock market opened in reverse gear on Tuesday as global equity selling spilled into Zurich. By 09:10 CET, the Swiss Market Index (SMI) was down around 0.3% at 12,565 points, after opening roughly 0.4% weaker near 12,560 compared with Monday’s close of 12,597.82. finanzen.ch+1 Selling pressure persisted into late morning: around

18 November 2025

Financial News · Market Analysis · SMI Index · Stock Market · Swiss Economy

AI Pathology Breakthrough: Roche’s Lung Cancer Diagnostic Makes FDA History

In April 2025, Roche’s Ventana TROP2 (EPR20043) RxDx test became the first AI-powered diagnostic to receive FDA Breakthrough Device Designation. The device pairs an immunohistochemistry stain for TROP2 with a digital pathology AI algorithm that runs in Roche’s Navify system to analyze NSCLC biopsy slides. The AI calculates a Normalized Membrane Ratio (NMR), the ratio of surface TROP2 to internal TROP2, to classify tumors as TROP2-positive or -negative. The Ventana TROP2 RxDx is a full diagnostic system, including Roche’s slide scanners, the Navify image management software, the Ventana TROP2 IHC kit, and the AI algorithm. A positive NMR score thresholds

17 July 2025

AI in Healthcare · FDA Approvals · Medical Diagnostics · NYSE:AZN · NYSE:RHHBY · Oncology · Technological Innovation